CLINICAL AND IMMUNOLOGICAL INDICES IN HIV-INFECTED PATIENTS WITH VIRAL SKIN DISEASES
- PMID: 30829595
CLINICAL AND IMMUNOLOGICAL INDICES IN HIV-INFECTED PATIENTS WITH VIRAL SKIN DISEASES
Abstract
The aim of the study was the evaluation of the several immunological indices in HIV/AIDS-infected patients with viral skin lesions. 38 HIV/AIDS patients 18-53 years of age (20 men and 18 women) with skin pathology have been enrolled in the study. The skin pathology included 20 cases with recurrent herpes simplex and 18 with chronic ulcerative herpes simplex virus infections. There were 25 patients with HIV infection stage 2, and 13 with stage 3. Immunological studies were carried out before the treatment and 2 months after it. Together with ART, the treatment in cases of chronic ulcerative herpes and recurrent herpes simplex included acyclovir, 400 mg 5 times a day, and Cidipol solution externally. Group 1 received ART according to the standard antiviral therapy protocol, Group 2 received ART, antiviral medicines and Cidipol solution externally. The study showed that after 2 months of the complex therapy with Cidipol, patients from the treatment group demonstrated a reliable increase in the count of CD3+, CD16+ and CD56+ cells and phagocytic activity of neutrophils. There was also a significant decrease (approaching to the normal values) of the levels of immune globulins and heterophil haemolysins. The present study of the immune responses in the cases of skin viral lesions in HIV/AIDS-infected patients contributes to the better understanding of the cellular and cytokine responses, thereby enabling us to increase the efficacy of the therapy and prevention of viral dermatoses in immunocompromised patients.
Similar articles
-
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.Int J STD AIDS. 2014 Aug;25(9):676-82. doi: 10.1177/0956462413518034. Epub 2014 Feb 17. Int J STD AIDS. 2014. PMID: 24535691
-
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).Clin Infect Dis. 1994 Apr;18(4):570-8. doi: 10.1093/clinids/18.4.570. Clin Infect Dis. 1994. PMID: 8038312
-
Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.AIDS. 2000 Jun 16;14(9):1211-7. doi: 10.1097/00002030-200006160-00019. AIDS. 2000. PMID: 10894286 Clinical Trial.
-
Antiviral agents.Dermatol Clin. 2001 Jan;19(1):23-34. doi: 10.1016/s0733-8635(05)70227-8. Dermatol Clin. 2001. PMID: 11155584 Review.
-
Drug-resistant herpes simplex virus in HIV infected patients.Acta Dermatovenerol Croat. 2008;16(4):204-8. Acta Dermatovenerol Croat. 2008. PMID: 19111144 Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials